Literature DB >> 31657895

DARK Classics in Chemical Neuroscience: NBOMes.

Christian B M Poulie, Anders A Jensen, Adam L Halberstadt, Jesper L Kristensen.   

Abstract

N-Benzylphenethylamines, commonly known as NBOMes, are synthetic psychedelic compounds derived from the phenethylamine class of psychedelics (2C-X compounds), which originally have been derived from the naturally occurring alkaloid mescaline. Analogously to their parent compounds and other classical psychedelics, such as psilocybin and lysergic acid diethylamide (LSD), NBOMes are believed to exert their main pharmacological effects through activation of serotonin 2A (5-HT2A) receptors. Since their introduction as New Psychoactive Substances (NPSs) in 2010, NBOMes have been widely used for recreational purposes; this has resulted in numerous cases of acute toxicity, sometimes with lethal outcomes, leading to the classification of several NBOMes as Schedule I substances in 2013. However, in addition to their recreational use, the NBOMe class has yielded several important biochemical tools, including [11C]Cimbi-36, which is now being used in positron emission tomography (PET) studies of the 5-HT2A and 5-HT2C receptors in the mammalian brain, and 25CN-NBOH, one of the most selective 5-HT2A receptor agonists developed to date. In this Review, the history, chemistry, structure-activity relationships, ADME (absorption, distribution, metabolism, and excretion) properties, and safety profiles of NBOMes will be outlined and discussed.

Entities:  

Keywords:  5-HT2A receptor; N-Benzylphenethylamines; novel psychoactive substance; psychedelics

Year:  2019        PMID: 31657895      PMCID: PMC9191638          DOI: 10.1021/acschemneuro.9b00528

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   5.780


  122 in total

1.  Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.

Authors:  Albert Garcia-Romeu; Roland R Griffiths; Matthew W Johnson
Journal:  Curr Drug Abuse Rev       Date:  2014

2.  Synthesis of [13C6]-labelled phenethylamine derivatives for drug quantification in biological samples.

Authors:  Morten Karlsen; HuiLing Liu; Thomas Berg; Jon Eigill Johansen; Bård Helge Hoff
Journal:  J Labelled Comp Radiopharm       Date:  2014-03-14       Impact factor: 1.921

Review 3.  Positron emission tomography in CNS drug discovery and drug monitoring.

Authors:  Markus Piel; Ingo Vernaleken; Frank Rösch
Journal:  J Med Chem       Date:  2014-09-10       Impact factor: 7.446

4.  Structure--activity relationships of one-ring psychotomimetics.

Authors:  A T Shulgin; T Sargent; C Naranjo
Journal:  Nature       Date:  1969-02-08       Impact factor: 49.962

5.  Determination of 4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine (25B-NBOMe) in serum and urine by high performance liquid chromatography with tandem mass spectrometry in a case of severe intoxication.

Authors:  Justin L Poklis; Carol R Nanco; Michelle M Troendle; Carl E Wolf; Alphonse Poklis
Journal:  Drug Test Anal       Date:  2013-09-02       Impact factor: 3.345

6.  A Case Review of the First Analytically Confirmed 25I-NBOMe-Related Death in Washington State.

Authors:  Lyndsey M Lowe; Brianna L Peterson; Fiona J Couper
Journal:  J Anal Toxicol       Date:  2015-10       Impact factor: 3.367

Review 7.  Psychedelics.

Authors:  David E Nichols
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

8.  Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.

Authors:  Roland R Griffiths; Matthew W Johnson; Michael A Carducci; Annie Umbricht; William A Richards; Brian D Richards; Mary P Cosimano; Margaret A Klinedinst
Journal:  J Psychopharmacol       Date:  2016-12       Impact factor: 4.153

9.  Tolerance and Tachyphylaxis to Head Twitches Induced by the 5-HT2A Agonist 25CN-NBOH in Mice.

Authors:  Tobias Buchborn; Taylor Lyons; Thomas Knöpfel
Journal:  Front Pharmacol       Date:  2018-02-06       Impact factor: 5.810

10.  Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases.

Authors:  Peter Gasser; Dominique Holstein; Yvonne Michel; Rick Doblin; Berra Yazar-Klosinski; Torsten Passie; Rudolf Brenneisen
Journal:  J Nerv Ment Dis       Date:  2014-07       Impact factor: 2.254

View more
  6 in total

1.  Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor.

Authors:  Kuglae Kim; Tao Che; Ouliana Panova; Jeffrey F DiBerto; Jiankun Lyu; Brian E Krumm; Daniel Wacker; Michael J Robertson; Alpay B Seven; David E Nichols; Brian K Shoichet; Georgios Skiniotis; Bryan L Roth
Journal:  Cell       Date:  2020-09-17       Impact factor: 41.582

2.  A qualitative descriptive analysis of effects of psychedelic phenethylamines and tryptamines.

Authors:  Joseph J Palamar; Patricia Acosta
Journal:  Hum Psychopharmacol       Date:  2020-01-07       Impact factor: 1.672

3.  Serotonin 2A Receptor (5-HT2AR) Activation by 25H-NBOMe Positional Isomers: In Vitro Functional Evaluation and Molecular Docking.

Authors:  Eline Pottie; Olga V Kupriyanova; Asher L Brandt; Robert B Laprairie; Vadim A Shevyrin; Christophe P Stove
Journal:  ACS Pharmacol Transl Sci       Date:  2021-02-25

Review 4.  Three Naturally-Occurring Psychedelics and Their Significance in the Treatment of Mental Health Disorders.

Authors:  Nataliya Vorobyeva; Alena A Kozlova
Journal:  Front Pharmacol       Date:  2022-06-28       Impact factor: 5.988

5.  Discovery of β-Arrestin-Biased 25CN-NBOH-Derived 5-HT2A Receptor Agonists.

Authors:  Christian B M Poulie; Eline Pottie; Icaro A Simon; Kasper Harpsøe; Laura D'Andrea; Igor V Komarov; David E Gloriam; Anders A Jensen; Christophe P Stove; Jesper L Kristensen
Journal:  J Med Chem       Date:  2022-09-13       Impact factor: 8.039

Review 6.  Molecular Mechanisms of Action of Novel Psychoactive Substances (NPS). A New Threat for Young Drug Users with Forensic-Toxicological Implications.

Authors:  Arianna Giorgetti; Jennifer P Pascali; Paolo Fais; Guido Pelletti; Andrea Gabbin; Giorgia Franchetti; Giovanni Cecchetto; Guido Viel
Journal:  Life (Basel)       Date:  2021-05-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.